A Multicenter, 52-week, provider- randomized, pragmatic trial to assess the differences in ABILIFY MYCITE - a digital medicine system (DMS) versus treatment as usual (TAU) for adults with schizophrenia, bipolar I disorder, or major depression currently using Aripiprazole. The purpose of this research is to look at medication adherence in adults with schizophrenia (including schizoaffective disorder), bipolar 1 disorder, or major depressive disorder when using the ABILIFY MYCITE System. The ABILIFY MYCITE System is a drug-device combination that includes the Aripiprazole pill, currently prescribed by a doctor, with a digital medicine system that helps both the patient and the doctor track medication ingestion. We are enrolling patients with the above diagnosis who are taking Aripiprazole. The study duration is a total of 12 months and involves four study visits where we will collect height, weight, vital signs and information about the satisfaction regarding the ABILIFY MYCITE system. 

The MYCITE system has four parts:

  • ABILIFY MYCITE: aripiprazole pill with ingestible sensor
  • MYCITE PATCH: placed on the lower chest. (detects when the pill is swallowed).
  • MYCITE APP: free mobile app downloaded on a smartphone. Allows access to medication ingestion data.
  • MYCITE Dashboard: web based portal that providers can log into and see medication ingestion data.

*A phone will be provided if the patient doesn’t have one.

*We are only enrolling Veterans*

For more information or to see if you qualify, contact the study coordinators at (713) 798-7786, (713) 798-7658 or by email at


Cristin Rodriguez, Norma Moncayo brainresearch@bcm.eduPhone 1: (713) 798-7786
IRB: h-45019




Feb 26, 2019